A Retrospective Observational Study to Evaluate the Clinical Outcomes and Routine Management of Patients With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
Phase of Trial: Phase IV
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Idelalisib (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms RETRO-idel
- Sponsors Gilead Sciences
- 11 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.
- 11 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2019.
- 11 Oct 2018 Status changed from not yet recruiting to recruiting.